Eledon Pharma Analyst Ratings
Eledon Pharma Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 09/27/2023 | 687.4% | Noble Capital Markets | → $10 | Initiates Coverage On | → Outperform |
| 08/22/2023 | 608.66% | Cantor Fitzgerald | → $9 | Reiterates | Overweight → Overweight |
| 05/26/2023 | 1868.5% | HC Wainwright & Co. | → $25 | Reiterates | Buy → Buy |
| 06/01/2022 | 1947.24% | SVB Leerink | $33 → $26 | Maintains | Outperform |
| 11/24/2021 | 1868.5% | HC Wainwright & Co. | $35 → $25 | Maintains | Buy |
| 04/27/2021 | 2498.43% | SVB Leerink | $34 → $33 | Maintains | Outperform |
| 03/23/2021 | 1868.5% | Cantor Fitzgerald | → $25 | Initiates Coverage On | → Overweight |
| 02/08/2021 | 2577.17% | SVB Leerink | → $34 | Initiates Coverage On | → Outperform |
| 日期 | 上行/下行空间 | 分析师公司 | 价格目标变化 | 评级变化 | 之前/现今评级 |
|---|---|---|---|---|---|
| 09/27/2023 | 687.4% | Noble资本市场 | → $10 | 开始覆盖 | →买入 |
| 08/22/2023 | 608.66% | Cantor Fitzgerald | → $9 | 重申 | 超重 → 超重 |
| 05/26/2023 | 1868.5% | HC Wainwright & Co. | → 25美元 | 重申 | 买入 → 买入 |
| 06/01/2022 | 1947.24% | SVB Leerink | $33 → $26 | 维持 | 跑赢大盘 |
| 11/24/2021 | 1868.5% | HC Wainwright & Co. | $35 → $25 | 维持 | 买入 |
| 04/27/2021 | 2498.43% | SVB Leerink | $34 → $33 | 维持 | 跑赢大盘 |
| 03/23/2021 | 1868.5% | Cantor Fitzgerald | → 25美元 | 开始覆盖 | → 超配 |
| 02/08/2021 | 2577.17% | SVB Leerink | →34美元 | 开始覆盖 | →买入 |
What is the target price for Eledon Pharma (ELDN)?
Eledon Pharma (ELDN)的目标价是多少？
The latest price target for Eledon Pharma (NASDAQ: ELDN) was reported by Noble Capital Markets on September 27, 2023. The analyst firm set a price target for $10.00 expecting ELDN to rise to within 12 months (a possible 687.40% upside). 3 analyst firms have reported ratings in the last year.
纳斯达克（NASDAQ）的Eledon Pharma公司最新的目标价格是由Noble Capital Markets在2023年9月27日发布的。该分析师公司设定了10.00美元的价格目标，预计ELDN在12个月内上升（可能达到687.40％的上涨空间）。在过去的一年中，有3家分析师公司报告了评级。
What is the most recent analyst rating for Eledon Pharma (ELDN)?
Eledon Pharma (ELDN)最近的分析师评级是什么？
The latest analyst rating for Eledon Pharma (NASDAQ: ELDN) was provided by Noble Capital Markets, and Eledon Pharma initiated their outperform rating.
纳斯达克（NASDAQ）的Eledon Pharma公司最新的分析师评级由Noble Capital Markets提供，并开始推出其表现评级。
When is the next analyst rating going to be posted or updated for Eledon Pharma (ELDN)?
Eledon Pharma (ELDN)的下一个分析师评级将何时发布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Eledon Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Eledon Pharma was filed on September 27, 2023 so you should expect the next rating to be made available sometime around September 27, 2024.
分析师会在进行广泛的研究（包括查阅公开的基本报表、与Eledon Pharma的高管和客户交谈以及收听业绩会议电话）后才会评定股票评级。大多数分析师每三个月会进行一次评级，并且每年每个公司每家分析师公司应该会提供4个评级。Eledon Pharma的上一个评级是2023年9月27日提交的，因此您可以预期下一个评级将在2024年9月27日左右公布。
Is the Analyst Rating Eledon Pharma (ELDN) correct?
分析师对Eledon Pharma (ELDN)的评级是否正确？
While ratings are subjective and will change, the latest Eledon Pharma (ELDN) rating was a initiated with a price target of $0.00 to $10.00. The current price Eledon Pharma (ELDN) is trading at is $1.27, which is within the analyst's predicted range.
虽然评级是主观的并且会发生变化，但是最新的Eledon Pharma（ELDN）评级是以0.00美元至10.00美元的价格目标启动的。目前，Eledon Pharma（ELDN）的股价为1.27美元，处于分析师预测的区间之内。
译文内容由第三方软件翻译。